Plain-English translation of NCT05009992 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that may help fight diffuse midline gliomas — aggressive brain tumors that develop in the middle of the brain — often given together with radiation therapy and sometimes with another drug called . The study enrolls children and young adults at different stages of their disease: those newly diagnosed, those who have finished radiation, and those whose tumors have come back or grown.
Diffuse midline gliomas are very serious and difficult to treat with standard approaches alone. This trial is exploring whether combining this medication with radiation therapy — and possibly adding a second medication — can help slow tumor growth and improve survival in young patients.
You likely qualify if…
You likely don't qualify if…
If you qualify for one of the currently enrolling groups, you would take oral medication (pills) either before a tumor biopsy, during radiation therapy sessions, or during a maintenance phase lasting 4-week cycles. Some participants may also receive repeat infusions of a different treatment directly into the tumor area. You would have regular visits to monitor how you're responding and watch for any side effects, with the specific schedule depending on your disease stage and which treatment group you join.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States